Article
The Cancer Genome Atlas Project in Bladder Cancer.
Cancer treatment and research - 1 Jan 2000
Rodriguez-Vida Alejo, Lerner Seth P, Bellmunt Joaquim
Abstract excerpt
Bladder cancer (BC) remains an aggressive disease with a poor prognosis, especially for patients with metastatic disease who have a limited median overall survival of 14 months. Urothelial carcinomas harbor frequent molecular dysregulations including recurrent mutations and copy number alteration, some of which could be potential therapeutic targets. However, no molecularly targeted agents have been approved to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
